Pfizer: When Does Replacement Become Growth?

Pfizer raised its full year forecast yesterday after reporting third quarter revenue of roughly $16.6 billion, about the same as a year earlier. Medicines such as Padcev and Nurtec are growing, but much of that progress is replacing sales Pfizer is losing elsewhere. Sustained growth requires those gains to pull ahead of the declines.

In its third quarter results, Pfizer lifted its 2026 revenue outlook to $62 billion to $64 billion, from $60.5 billion to $62.5 billion. Management also raised and narrowed its forecast for adjusted diluted earnings per share to $2.95 to $3.05, from $2.80 to $3.00. Those are management's expectations for the year.

Three numbers tell different parts of Pfizer's sales story:

Operational growth removes the effect of currency movements. It still includes changes in prices and the mix of products sold. The launched and acquired group is also a selection defined by management, rather than the entire business outside COVID.

The 32% figure shows how quickly that group is expanding. Its $3.8 billion sales base helps explain why strong growth there can coexist with flat revenue across a much larger company. Both numbers belong in the recovery story.

Padcev offers a concrete example of how a medicine can grow. Pfizer reported 55% operational revenue growth for the cancer treatment in the third quarter compared with a year earlier. It cited increased market share as an initial treatment for advanced urothelial cancer, which affects the lining of the urinary tract, and uptake in an additional bladder cancer treatment setting.

There is a clinical foundation for its use in advanced disease. In December 2023, the FDA approved Padcev with pembrolizumab for locally advanced or metastatic urothelial cancer. In the supporting randomized trial, the combination improved survival compared with platinum based chemotherapy in patients who had received no previous systemic therapy for advanced disease.

Becoming an initial treatment option lets a medicine reach patients earlier in their care. Approval for another patient group can expand that opportunity. Sales then depend on doctors choosing the treatment, patients being able to access it and how long treatment continues.

Nurtec has a different path. Its US label covers treating migraine attacks in adults and, with a different dosing schedule, preventing episodic migraine in adults. Pfizer reported 33% operational revenue growth for Nurtec ODT/Vydura in the third quarter compared with a year earlier, driven primarily by US demand and uptake in certain international launches.

More patients and more countries can support sales growth. To judge how durable that growth might be, investors also need to understand competition, access and how much revenue Pfizer retains after discounts.

The growing medicines have substantial declines to absorb. Paxlovid revenue fell 63% operationally and Comirnaty fell 29%. The Prevnar vaccine family also declined 10% operationally, with Pfizer citing lower vaccination rates and erosion of its adult market share in the US. All three comparisons are against the third quarter of 2025.

Prevnar makes the challenge clearer. Even as Pfizer works through the retreat from pandemic sales, established products face ordinary competition and changes in demand.

Eliquis adds another wrinkle. Its revenue grew 25% operationally, but Pfizer attributed the increase partly to higher US net pricing, including lower rebates and a more favorable mix of sales channels, alongside higher global demand. Net price is what the company retains after relevant discounts and rebates.

So a 25% sales increase does not mean 25% more patients. Wider use and better pricing can both help earnings, but their staying power may differ. Understanding which is doing the work helps investors judge whether growth can continue.

The earnings comparison shows why the higher forecast deserves some perspective. Reported diluted earnings per share fell to $0.56 from $0.62. Adjusted diluted earnings per share, Pfizer's non GAAP measure, stayed at $0.87. These comparisons are also against the third quarter of 2025.

Replacing sales takes spending, too. Future medicines must move through research, regulatory review and commercial adoption. Management says productivity improvements are enabling continued investment in its pipeline. Some savings can therefore help fund future products rather than become extra cash available to shareholders.

The next results should help answer three practical questions:

The risk is that growing medicines slow while established products keep losing sales, leaving cost reductions to defend earnings. As patent and regulatory protections end, competing versions can add pressure on sales and prices.

Pfizer's quarter shows meaningful progress in replacing lost revenue. A stronger recovery would show that the growing medicines can lift the whole business while helping pay for the next generation.